What are accolade's twelve-month price targets?

16 analysts have issued twelve-month price targets for Accolade's stock. Their ACCD share price forecasts range from $10.00 to $17.00. On average, they predict the company's stock price to reach $13.91 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.

Is accolade a good stock to buy now?

According to analysts' consensus price target of $13.91, Accolade has a forecasted downside of 3.3% from its current price of $14.38. Accolade has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Which ETFs hold accolade (ACCD) stock?

ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares Micro-Cap ETF (IWC). iShares U.S. Healthcare Providers ETF (IHF).

Does market cap include securities convertible into common equity securities?

It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).